Tsang 2004.

Methods	Randomised double‐blind, prospective placebo controlled trial with study duration of 52 weeks. There were no dropouts.
Participants	60 participants (mean age 56.4 years, 38 females) with HRCT proven bronchiectasis. Fluticasone group: n = 30, age: mean 56.1 (SD 14). Placebo group: n = 30, age: mean 56.7 (SD 11.3). 16 were P aeruginosa colonised and 44 were not. Inclusion: absence of asthma or other unstable systemic disease; and "steady state" bronchiectasis (< 20% alteration of 24‐hour sputum volume, FEV1 and FVC) and absence of deterioration in respiratory symptoms at baseline visit. Exclusion: unreliable clinic attendance, known adverse reaction to fluticasone and asthma.
Interventions	Inhaled fluticasone 500 µg twice daily by accuhaler or placebo for 52 weeks.
Outcomes	The participants were followed up at ‐2, ‐1, 0, 4, 12, 24, 36, 48 and 52 weeks after commencement of therapy for measurement of FeNO.
Notes	Data not included in the final analysis since medians and inter‐quartile range reported in this study. The study was supported by a CRCG Grant of the University of Hong Kong. The Accuhalers were donated by GlaxoWellcome, China.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No information was provided within the published article about generation of randomisation.
Allocation concealment (selection bias)	Unclear risk	No mention on allocation concealment.
Blinding (performance bias and detection bias) All outcomes	Low risk	Quote: "performed a double blind, placebo controlled study".
Incomplete outcome data (attrition bias) All outcomes	Low risk	There were no dropouts.
Selective reporting (reporting bias)	Low risk	No suggestion that selective reporting may have been done.
Other bias	High risk	Baseline value of the 2 groups were significantly different.